Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P19429: Variant p.Lys36Gln

Troponin I, cardiac muscle
Gene: TNNI3
Feedback?
Variant information Variant position: help 36 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Lysine (K) to Glutamine (Q) at position 36 (K36Q, p.Lys36Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (K) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMD1FF. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 36 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 210 The length of the canonical sequence.
Location on the sequence: help PAPIRRRSSNYRAYATEPHA K KKSKISASRKLQLKTLLLQI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PAP------IRRRSS-NYRAYATEPHAKKKSKISASRKLQLKTLLLQI

                              PAP------IRRQSSANYRAYATEPHAKKKSKISASRKLQL

Mouse                         PAP------VRRRSSANYRAYATEPHAKKKSKISASRKLQL

Rat                           PAP------VRRRSSANYRAYATEPHAKKKSKISASRKLQL

Bovine                        PPP------VRRRSSANYRAYATEPHAKKKSKISASRKLQL

Rabbit                        PAP------VRRRSSANYRAYATEPHAKSKKKISASRKLQL

Cat                           PAP------VRRRSSANYRAYATEPHAKKKSKISASRKLQL

Horse                         PPP------VRRRSSANYRAYATEPHAKKKSKISASRKLQL

Xenopus laevis                PPPAAPPPLIRRRSSANYRSYATEPQVKRKPKISASRKLQL

Caenorhabditis elegans        QERELKKAEVRKRME-----EAAKKGSKKKGFLTPERKKKL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 210 Troponin I, cardiac muscle
Region 1 – 43 Disordered
Region 32 – 79 Involved in binding TNC
Modified residue 23 – 23 Phosphoserine; by PKA and PKD/PRKD1
Modified residue 24 – 24 Phosphoserine; by PKA and PKD/PRKD1
Modified residue 26 – 26 Phosphotyrosine
Modified residue 31 – 31 Phosphothreonine; by STK4/MST1
Modified residue 42 – 42 Phosphoserine; by PKC/PRKCE
Modified residue 44 – 44 Phosphoserine; by PKC/PRKCE
Modified residue 51 – 51 Phosphothreonine; by STK4/MST1



Literature citations
Identification and functional characterization of cardiac troponin I as a novel disease gene in autosomal dominant dilated cardiomyopathy.
Carballo S.; Robinson P.; Otway R.; Fatkin D.; Jongbloed J.D.; de Jonge N.; Blair E.; van Tintelen J.P.; Redwood C.; Watkins H.;
Circ. Res. 105:375-382(2009)
Cited for: VARIANTS CMD1FF GLN-36 AND LYS-185;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.